中银国际表示,再鼎医药(09688.HK) 首季业绩疲弱,收入按年下降6%至9,960万美元,低于市场预期9%,主要受到则乐降幅超预期以及艾加莫德医保降价影响。持续加大的研发投入导致净亏损扩大至5,100万美元。管理层预计2026年剩余时间收入将逐渐改善,但全年增长仍将受压,恢复增长预计要到2027年。该行指出,管线进展仍是今季最大亮点,其中zoci(DLL3 ADC)继续展现差异化潜力。在...
Source Link中银国际表示,再鼎医药(09688.HK) 首季业绩疲弱,收入按年下降6%至9,960万美元,低于市场预期9%,主要受到则乐降幅超预期以及艾加莫德医保降价影响。持续加大的研发投入导致净亏损扩大至5,100万美元。管理层预计2026年剩余时间收入将逐渐改善,但全年增长仍将受压,恢复增长预计要到2027年。该行指出,管线进展仍是今季最大亮点,其中zoci(DLL3 ADC)继续展现差异化潜力。在...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.